Skip to content

Efficacy and safety of rush immunotherapy for Japanese cedar pollinosis

Efficacy and safety of rush immunotherapy for Japanese cedar pollinosis - Efficacy and safety of rush immunotherapy for Japanese cedar pollinosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012117
Enrollment
10
Registered
2013-10-27
Start date
2013-10-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

Administration standardized Japanese cedar extract to maintenance phase for a week

Sponsors

National Sagamihara Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patient with allergic rhinitis, who have specific IgE RAST score 2 or skin prick test positive for cedar pollen. 2) Patient who have typical allergic rhinitis symptoms year. 3) Written informed consent is required.

Exclusion criteria

Exclusion criteria: 1) Patients who have received immunotherapy. 2) Uncontrolled asthma patients. 3) Patients who were judged to be unsuitable for patient enrollment by their doctor.

Design outcomes

Primary

MeasureTime frame
Symptom score, Medication score, QOL score, Adverse reaction

Secondary

MeasureTime frame
Change of parameters in blood

Countries

Japan

Contacts

Public ContactTomoyuki Asaumi

National Sagamihara Hospital Pediatrics

ocean19oranges@yahoo.co.jp042-742-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026